Evidence map›Paper›PMID 37207350›Full record

ArticleDatabase : the journal of biological databases and curation2023

CenhANCER: a comprehensive cancer enhancer database for primary tissues and cell lines.

Zhi-Hui Luo, Meng-Wei Shi, Yuan Zhang, Dan-Yang Wang, Yi-Bo Tong, Xue-Ling Pan, ShanShan Cheng

Open access · goldAbstract read
In one paragraph

Article in Database : the journal of biological databases and curation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhi-Hui LuoDepartment of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan, Hubei 430030, P.R. China.
Meng-Wei ShiHubei Hongshan Laboratory, College of Biomedicine and Health, Huazhong Agricultural University, No. 1, Shizishan Street, Wuhan, Hubei 430070, China.
Yuan ZhangHubei Hongshan Laboratory, College of Biomedicine and Health, Huazhong Agricultural University, No. 1, Shizishan Street, Wuhan, Hubei 430070, China.
Dan-Yang WangHubei Hongshan Laboratory, College of Biomedicine and Health, Huazhong Agricultural University, No. 1, Shizishan Street, Wuhan, Hubei 430070, China.
Yi-Bo TongHubei Hongshan Laboratory, College of Biomedicine and Health, Huazhong Agricultural University, No. 1, Shizishan Street, Wuhan, Hubei 430070, China.
Xue-Ling PanHubei Hongshan Laboratory, College of Biomedicine and Health, Huazhong Agricultural University, No. 1, Shizishan Street, Wuhan, Hubei 430070, China.
ShanShan ChengDepartment of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan, Hubei 430030, P.R. China.ORCID 0000-0003-2676-7341
Huazhong Agricultural University · CNHuazhong University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enhancers, which are key tumorigenic factors with wide applications for subtyping, diagnosis and treatment of cancer, are attracting increasing attention in the cancer research. However, systematic analysis of cancer enhancers poses a challenge due to the lack of integrative data resources, especially those from tumor primary tissues. To provide a comprehensive enhancer profile across cancer types, we developed a cancer enhancer database CenhANCER by curating public resources including all the public H3K27ac ChIP-Seq data from 805 primary tissue samples and 671 cell line samples across 41 cancer types. In total, 57 029 408 typical enhancers, 978 411 super-enhancers and 226 726 enriched transcription factors were identified. We annotated the super-enhancers with chromatin accessibility regions, cancer expression quantitative trait loci (eQTLs), genotype-tissue expression eQTLs and genome-wide association study risk single nucleotide polymorphisms (SNPs) for further functional analysis. The identified enhancers were highly consistent with accessible chromatin regions in the corresponding cancer types, and all the 10 super-enhancer regions identified from one colorectal cancer study were recapitulated in our CenhANCER, both of which testified the high quality of our data. CenhANCER with high-quality cancer enhancer candidates and transcription factors that are potential therapeutic targets across multiple cancer types provides a credible resource for single cancer analysis and for comparative studies of various cancer types. Database URL http://cenhancer.chenzxlab.cn/.

Indexed as

Genome-Wide Association StudyNeoplasmsCell LineChromatinEnhancer Elements, GeneticHumansTranscription FactorsChromatinTranscription Factors

Identifiers

PMID37207350
PMCPMC10198702
OpenAlexW4377142576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.